Pharmacologic Approaches to the Treatment of Huntington's Disease
Identifieur interne : 001029 ( Main/Exploration ); précédent : 001028; suivant : 001030Pharmacologic Approaches to the Treatment of Huntington's Disease
Auteurs : Charles S. Venuto [États-Unis] ; Andrew Mcgarry [États-Unis] ; QING MA [États-Unis] ; Karl Kieburtz [États-Unis]Source :
- Movement disorders [ 0885-3185 ] ; 2012.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Huntington's disease (HD) is an inherited, progressive neurodegenerative disorder characterized by chorea, cognitive impairment, and behavioral disturbances. Despite advances in diagnosis and improved understanding of HD, treatment remains difficult due to challenging symptoms and a paucity of approved therapeutic interventions. Nonpharmacologic and pharmacologic strategies have been evaluated; regarding the latter, over 80 agents of various classes have been investigated in clinical trials or examined in case reports. Symptomatic treatment, however, is generally confined to antidopaminergic agents for motor dysfunction and antidepressants for mood disorders, while treatment for cognitive dysfunction remains vacant. Several different mechanisms to modify symptoms and disease progression have been targeted in clinical trials. This article reviews some of the more common pharmacologic treatments used for HD, discusses data regarding suboptimal agents that have been tested, and surveys treatments under investigation.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000312
- to stream PascalFrancis, to step Curation: 002A02
- to stream PascalFrancis, to step Checkpoint: 000102
- to stream Main, to step Merge: 001081
- to stream Main, to step Curation: 001029
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Pharmacologic Approaches to the Treatment of Huntington's Disease</title><author><name sortKey="Venuto, Charles S" sort="Venuto, Charles S" uniqKey="Venuto C" first="Charles S." last="Venuto">Charles S. Venuto</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo</s1><s2>Buffalo, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Translational Pharmacology Research Core, New York State Center of Excellence in Bioinformatics and Life Sciences</s1><s2>Buffalo, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Mcgarry, Andrew" sort="Mcgarry, Andrew" uniqKey="Mcgarry A" first="Andrew" last="Mcgarry">Andrew Mcgarry</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Qing Ma" sort="Qing Ma" uniqKey="Qing Ma" last="Qing Ma">QING MA</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo</s1><s2>Buffalo, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Translational Pharmacology Research Core, New York State Center of Excellence in Bioinformatics and Life Sciences</s1><s2>Buffalo, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">12-0106476</idno><date when="2012">2012</date><idno type="stanalyst">PASCAL 12-0106476 INIST</idno><idno type="RBID">Pascal:12-0106476</idno><idno type="wicri:Area/PascalFrancis/Corpus">000312</idno><idno type="wicri:Area/PascalFrancis/Curation">002A02</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000102</idno><idno type="wicri:doubleKey">0885-3185:2012:Venuto C:pharmacologic:approaches:to</idno><idno type="wicri:Area/Main/Merge">001081</idno><idno type="wicri:Area/Main/Curation">001029</idno><idno type="wicri:Area/Main/Exploration">001029</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Pharmacologic Approaches to the Treatment of Huntington's Disease</title><author><name sortKey="Venuto, Charles S" sort="Venuto, Charles S" uniqKey="Venuto C" first="Charles S." last="Venuto">Charles S. Venuto</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo</s1><s2>Buffalo, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Translational Pharmacology Research Core, New York State Center of Excellence in Bioinformatics and Life Sciences</s1><s2>Buffalo, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Mcgarry, Andrew" sort="Mcgarry, Andrew" uniqKey="Mcgarry A" first="Andrew" last="Mcgarry">Andrew Mcgarry</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Qing Ma" sort="Qing Ma" uniqKey="Qing Ma" last="Qing Ma">QING MA</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo</s1><s2>Buffalo, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Translational Pharmacology Research Core, New York State Center of Excellence in Bioinformatics and Life Sciences</s1><s2>Buffalo, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chorea</term><term>Huntington disease</term><term>Hyperkinesia</term><term>Nervous system diseases</term><term>Surgical approach</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Chorée de Huntington</term><term>Hyperkinésie</term><term>Syndrome choréique</term><term>Pathologie du système nerveux</term><term>Voie abord</term><term>Traitement</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Huntington's disease (HD) is an inherited, progressive neurodegenerative disorder characterized by chorea, cognitive impairment, and behavioral disturbances. Despite advances in diagnosis and improved understanding of HD, treatment remains difficult due to challenging symptoms and a paucity of approved therapeutic interventions. Nonpharmacologic and pharmacologic strategies have been evaluated; regarding the latter, over 80 agents of various classes have been investigated in clinical trials or examined in case reports. Symptomatic treatment, however, is generally confined to antidopaminergic agents for motor dysfunction and antidepressants for mood disorders, while treatment for cognitive dysfunction remains vacant. Several different mechanisms to modify symptoms and disease progression have been targeted in clinical trials. This article reviews some of the more common pharmacologic treatments used for HD, discusses data regarding suboptimal agents that have been tested, and surveys treatments under investigation.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Venuto, Charles S" sort="Venuto, Charles S" uniqKey="Venuto C" first="Charles S." last="Venuto">Charles S. Venuto</name></region><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><name sortKey="Mcgarry, Andrew" sort="Mcgarry, Andrew" uniqKey="Mcgarry A" first="Andrew" last="Mcgarry">Andrew Mcgarry</name><name sortKey="Qing Ma" sort="Qing Ma" uniqKey="Qing Ma" last="Qing Ma">QING MA</name><name sortKey="Qing Ma" sort="Qing Ma" uniqKey="Qing Ma" last="Qing Ma">QING MA</name><name sortKey="Qing Ma" sort="Qing Ma" uniqKey="Qing Ma" last="Qing Ma">QING MA</name><name sortKey="Venuto, Charles S" sort="Venuto, Charles S" uniqKey="Venuto C" first="Charles S." last="Venuto">Charles S. Venuto</name><name sortKey="Venuto, Charles S" sort="Venuto, Charles S" uniqKey="Venuto C" first="Charles S." last="Venuto">Charles S. Venuto</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001029 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001029 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:12-0106476
|texte= Pharmacologic Approaches to the Treatment of Huntington's Disease
}}
| This area was generated with Dilib version V0.6.23. |  |